The Influence of an E-learning Program on Recognition of Actinic Keratosis

Sponsor
Maastricht University Medical Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05987553
Collaborator
(none)
32
1
39
0.8

Study Details

Study Description

Brief Summary

The evaluation on the diagnostic accuracy of actinic keratosis recognition by general practitioners before and after participation on an e-learning program.

Condition or Disease Intervention/Treatment Phase
  • Other: e-learning program

Detailed Description

Actinic keratosis is defined as the most frequent common intra-epithelial neoplasm in the Caucasian population, with an increasing prevalence. If left untreated, actinic keratosis has the potency to develop into a cutaneous squamous-cell carcinoma. Treatment of actinic keratosis is aimed at both lesion reduction and to prevent malignant transformation. To achieve treatment adherence for patients, it is necessary to raise physician awareness about actinic keratosis.

This study primarily aimed to investigate whether the sensitivity of establishing a correct actinic keratosis diagnosis by general practitioners (in training) would increase after participating in an e-learning program about the recognition of actinic keratosis. This was achieved by comparing the results of a pre- and post-test completed by general practitioners which was incorporated in the e-learning program.

Study Design

Study Type:
Observational
Actual Enrollment :
32 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Influence of an E-learning Program on Recognition of Actinic Keratosis by General Practitioners). Implementation of Actinic Keratosis Guidelines Among General Practitioners.
Actual Study Start Date :
Jan 1, 2021
Actual Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Apr 1, 2024

Arms and Interventions

Arm Intervention/Treatment
General practitioners

All participants were general practitioners (in training).

Other: e-learning program
All participants participate in this intervention: an e-learning program about the recognition of actinic keratosis. The program exists of 30 cases. Each case exists of a question and thorough explanation including references to various sources.

Outcome Measures

Primary Outcome Measures

  1. Difference in sensitivity [Measurement by baseline and after finalising the e-learning program (same day up until 30 days)]

    Difference in sensitivity of participants in the recognition of actinic keratosis, before and after the use of an e-learning program (paired).

  2. Difference in specificity [Measurement by baseline and after finalising the e-learning program (same day up until 30 days)]

    Difference in specificity of participants in the recognition of actinic keratosis, before and after the use of an e-learning program (paired).

Secondary Outcome Measures

  1. Difference in area under the receiver operating characteristic (ROC) curve [Measurement by baseline and after finalising the e-learning program (same day up until 30 days)]

    Difference in area under the curve of participants in the recognition of actinic keratosis, before and after the use of an e-learning program.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 67 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • general practitioner in the Netherlands

  • access to e-learning module via phone/computer/tablet

  • knowledge of the Dutch language

Exclusion Criteria:
  • no knowledge of the Dutch language

  • different specialists than general practitioner

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ellen Oyen Maastricht Netherlands

Sponsors and Collaborators

  • Maastricht University Medical Center

Investigators

  • Principal Investigator: Klara Mosterd, prof.dr., Maastricht UMC+

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT05987553
Other Study ID Numbers:
  • 2020-1334
First Posted:
Aug 14, 2023
Last Update Posted:
Aug 14, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 14, 2023